Moderna, Inc. Hits New 52-Week High at $59.55, Signaling Recovery

Moderna, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 59.55 on March 4, 2026. This achievement marks a notable rebound from its 52-week low of USD 22.29, reflecting a substantial increase in the stock's value over the past year. Despite this recent uptick, Moderna's one-year performance shows a decline of 61.1%, contrasting sharply with the S&P 500's gain of 17.36% during the same period. The company's market capitalization stands at approximately USD 19,486 million, indicating its mid-cap status within the industry. Financial metrics reveal that Moderna is currently loss-making, with a return on equity of -32.62% and a debt-to-equity ratio of -0.60. The stock does not offer a dividend yield, and its price-to-book ratio is 2.25. As Moderna continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry, this recent high may serve as a pivotal point in its ongoing performance trajectory.